PriceTargets.com logo

Xencor - XNCR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.56
  • Forecasted Upside: 51.49%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$24.13 As of 12/20/2024 06:17 PM ET
▲ +0.12 (0.50%)

This chart shows the closing price for XNCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xencor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XNCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XNCR

Analyst Price Target is $36.56
▲ +51.49% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $36.56, with a high forecast of $50.00 and a low forecast of $28.00. The average price target represents a 51.49% upside from the last price of $24.13.

This chart shows the closing price for XNCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Xencor. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024Wells Fargo & CompanyInitiated CoverageOverweight$37.00
12/2/2024Piper SandlerUpgradeNeutral ➝ Overweight$20.00 ➝ $30.00
11/8/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$32.00 ➝ $34.00
11/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$27.00 ➝ $28.00
11/7/2024WedbushReiterated RatingOutperform$38.00
9/26/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$31.00 ➝ $34.00
9/9/2024WedbushReiterated RatingOutperform$34.00
8/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
8/6/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
7/31/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$30.00 ➝ $27.00
6/14/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$34.00 ➝ $32.00
6/14/2024Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$58.00 ➝ $40.00
6/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$32.00 ➝ $31.00
6/13/2024WedbushReiterated RatingOutperform$36.00 ➝ $34.00
5/10/2024WedbushBoost TargetOutperform ➝ Outperform$34.00 ➝ $36.00
4/16/2024BTIG ResearchLower TargetBuy ➝ Buy$56.00 ➝ $38.00
2/28/2024Piper SandlerReiterated RatingOverweight ➝ Neutral$37.00 ➝ $24.00
2/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$32.00
2/28/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$38.00 ➝ $34.00
2/28/2024WedbushLower TargetOutperform ➝ Outperform$36.00 ➝ $34.00
1/22/2024MizuhoLower TargetBuy ➝ Buy$59.00 ➝ $50.00
11/8/2023GuggenheimLower TargetBuy ➝ Buy$40.00 ➝ $34.00
11/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$36.00 ➝ $32.00
11/8/2023WedbushLower TargetOutperform ➝ Outperform$37.00 ➝ $36.00
8/7/2023Piper SandlerBoost Target$42.00 ➝ $45.00
8/4/2023WedbushReiterated RatingOutperform$37.00
5/19/2023Bank of AmericaInitiated CoverageBuy$42.00
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
5/9/2023GuggenheimLower Target$45.00 ➝ $39.00
2/24/2023Canaccord Genuity GroupLower TargetBuy$48.00 ➝ $42.00
2/24/2023EF Hutton Acquisition Co. IReiterated RatingBuy$42.00
2/23/2023Leerink PartnersReiterated RatingOutperform
2/13/2023JPMorgan Chase & Co.Boost TargetOverweight$37.00 ➝ $42.00
2/10/2023MizuhoReiterated RatingBuy$59.00
1/30/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$42.00
12/6/2022CowenInitiated CoverageOutperform
12/6/2022CowenInitiated CoverageOutperform
11/9/2022Canaccord Genuity GroupLower Target$50.00 ➝ $48.00
11/8/2022Royal Bank of CanadaLower TargetOutperform$40.00 ➝ $36.00
10/13/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$58.00
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$37.00
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$50.00
5/23/2022Piper SandlerLower TargetOverweight$66.00 ➝ $42.00
5/6/2022Piper SandlerLower Target$71.00 ➝ $66.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
2/24/2022HC WainwrightLower TargetBuy$61.00 ➝ $55.00
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$54.00
1/21/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$60.00
12/15/2021HC WainwrightInitiated CoverageBuy$61.00
11/9/2021BTIG ResearchReiterated RatingBuy
11/9/2021Piper SandlerLower TargetOverweight$75.00 ➝ $71.00
10/5/2021Piper SandlerBoost TargetOverweight$63.00 ➝ $75.00
9/28/2021GuggenheimLower TargetBuy$57.00 ➝ $50.00
8/5/2021Leerink PartnersLower TargetOutperform$57.00 ➝ $53.00
5/9/2021Leerink PartnersReiterated RatingBuy$57.00
5/6/2021WedbushLower TargetOutperform$52.00 ➝ $47.00
2/24/2021Leerink PartnersReiterated RatingOutperform
2/24/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $59.00
2/24/2021BarclaysBoost TargetUnderweight$31.00 ➝ $34.00
2/24/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$58.00
11/16/2020Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $56.00
11/6/2020Leerink PartnersBoost TargetOutperform$42.00 ➝ $46.00
9/8/2020Leerink PartnersLower TargetOutperform$42.00 ➝ $39.00
8/5/2020Leerink PartnersLower TargetOutperform$44.00 ➝ $42.00
8/5/2020MizuhoReiterated RatingBuy
7/21/2020MizuhoReiterated RatingBuy$52.00
7/8/2020Piper SandlerReiterated RatingBuy$46.00
7/8/2020MizuhoReiterated RatingBuy$52.00
5/10/2020NomuraReiterated RatingSell$21.00
5/7/2020MizuhoReiterated RatingBuy$52.00
3/4/2020BarclaysInitiated CoverageUnderweight$28.00
2/25/2020GuggenheimUpgradeNeutral ➝ Buy$43.00
2/17/2020MizuhoReiterated RatingBuy$52.00
1/30/2020Royal Bank of CanadaInitiated CoverageOutperform$44.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 20 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 20 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Xencor logo
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $24.13
Low: $23.52
High: $25.02

50 Day Range

MA: $23.46
Low: $21.01
High: $26.84

52 Week Range

Now: $24.13
Low: $15.31
High: $27.24

Volume

4,248,554 shs

Average Volume

626,483 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Xencor?

The following sell-side analysts have issued reports on Xencor in the last year: BMO Capital Markets, BTIG Research, JPMorgan Chase & Co., Mizuho, Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for XNCR.

What is the current price target for Xencor?

0 Wall Street analysts have set twelve-month price targets for Xencor in the last year. Their average twelve-month price target is $36.56, suggesting a possible upside of 51.5%. Mizuho has the highest price target set, predicting XNCR will reach $50.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $28.00 for Xencor in the next year.
View the latest price targets for XNCR.

What is the current consensus analyst rating for Xencor?

Xencor currently has 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XNCR will outperform the market and that investors should add to their positions of Xencor.
View the latest ratings for XNCR.

What other companies compete with Xencor?

Other companies that are similar to Xencor include Lantheus, Nuvalent, Legend Biotech, Blueprint Medicines and Elanco Animal Health. Learn More about companies similar to Xencor.

How do I contact Xencor's investor relations team?

Xencor's physical mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company's listed phone number is (626) 305-5900 and its investor relations email address is [email protected]. The official website for Xencor is www.xencor.com. Learn More about contacing Xencor investor relations.